Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Record breaking year at Evolution

Thu, 25th Mar 2010 08:25
2009 was a record breaking year on many fronts for investment management firm Evolution Group.Group income, private client income, investment banking income and assets under management all hit new highs.Total income more than doubled to £129.4m in 2009 from £63.9m, with investment banking income soaring 183% to £87m while private client income rose 23% to £42.4m.Assets under management jumped 37% to a record level of £5.2bn from £3.8bn the year before. Fund inflows at £322m were down from £550m the year before, but the number of private client accounts grew from 11,803 to 14,343. Statutory profit before tax was £11.1m, compared to a loss of £12.7m the year before. The company’s own adjusted profit before tax measurement showed profitability improving to £18,4m from £2.9m in 2008. ‘While activity levels last year remained depressed and investor sentiment proved highly sensitive to risk and volatility, the group nevertheless delivered an extremely impressive financial performance, with significant growth in both income and profit,’ said Martin Gray, chairman of Evolution.The final dividend has been increased by 34% to 1.70p, making the full year dividend 2.50p, up 24% on 2008’s level.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Evgen Pharma to advance SFX-01 trial with University of Dundee
5 Dec 2019

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, ...

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials
5 Dec 2019

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development
11 Nov 2019

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance
11 Nov 2019

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results
11 Nov 2019

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results
23 Sep 2019

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma upbeat on latest news from SFX-01 studies
23 Sep 2019

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial re...

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial
28 Aug 2019

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered ...